GlassScriptPhysician profile
Tiffany Kimble
NPI 1477034601
$4,189.72
in general payments reported to CMS, 2019-2025
50 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $592 · 2022: $427 · 2023: $1,487 · 2024: $1,236 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $478.18 | 2021-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $417.35 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Astellas Pharma US INC | $242.25 | 2021-2025 | Padcev, Xtandi, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $208.62 | 2022-2025 | Fruzaqla, Ninlaro, Vonvendi |
| Incyte Corporation | $198.44 | 2021-2023 | Jakafi, Monjuvi |
| Celgene Corporation | $191.84 | 2022-2023 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $183.76 | 2021-2024 | Calquence, Imfinzi |
| Daiichi Sankyo INC. | $173.44 | 2023-2024 | Enhertu |
| Gilead Sciences, INC. | $170.84 | 2022-2025 | |
| Abbvie INC. | $169.36 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $167.39 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $136.36 | 2023 | Amvuttra, Givlaari |
| Horizon Therapeutics Plc | $124.99 | 2023 | Uplizna |
| Pfizer INC. | $102.31 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $80.88 | 2022-2023 | Imbruvica |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Kimble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.